In this work, authors report on the PET-CT outcomes from the use of adjunctive statin therapy, rosuvastatin, in the intensive phase of tuberculosis (TB) treatment. Rosuvastatin had no impact on PET-CT changes when used as an adjunct to TB treatment. 8-weeks of TB treatment resulted in ~50% reduction in total lesion glycolysis (TLG), a metric that combines the volume of lung affected and metabolic activity.
- Gail B. Cross
- Intan P. Sari
- Nicholas I. Paton
